Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen and Bortezomib in Recurrent High-Grade Gliomas
NCT00108069Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2005
- Primary completion
- Mar 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamoxifen and bortezomib in glioma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Response (Stable Disease or Objective Response) at 6 weeks. Started Apr 2005; status: completed.
02
Drugs
tamoxifenbortezomib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00108069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00108069.